Hallmarks of Anaplastic Lymphoma Kinase Inhibitors with Its Quick Emergence of Drug Resistance

Yong-Fu Qiu1  Lian-Hua Song2  Gang-Long Jiang1  Zhen Zhang1,3  Xu-Yan Liu1  Guan Wang1,*

1 Novel Technology Center of Pharmaceutical Chemistry, Shanghai Institute of Pharmaceutical Industry, Co., Ltd., China State Institute of Pharmaceutical Industry, Shanghai, People’s Republic of China
2 Collaborative Innovation Center of Yangtze River Delta Region Green Pharmaceuticals, Zhejiang University of Technology, Hangzhou, People’s Republic of China
3 School of Chemistry and Chemical Engineering, Shanghai University of Engineering Science, Shanghai, People’s Republic of China

Pharmaceut Fronts 2022;4:e223–e236.

Abstract

Anaplastic lymphoma kinase (ALK) is one of the most popular targets for anticancer therapies. In the past decade, the use of anaplastic lymphoma tyrosine kinase inhibitors (ALK-TKIs), including crizotinib and ceritinib, has been a reliable and standard options for patients with lung cancer, particularly for patients with nonsmall cell lung carcinoma. ALK-targeted therapies initially benefit the patients, yet, resistance eventually occurs. Therefore, resistance mechanisms of ALK-TKIs and the solutions have become a formidable challenge in the development of ALK inhibitors. In this review, based on the knowledge of reported ALK inhibitors, we illustrated the crystal structures of ALK, summarized the resistance mechanisms of ALK-targeted drugs, and proposed potential therapeutic strategies to prevent or overcome the resistance.

Keywords
► ALK inhibitors
► drug resistance
► NSCLC

Introduction

Cancer is a group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body. Over the past few decades, the identification of the small-molecule inhibitors that shut down cell signaling pathways perpetually activated by cancer-specific mutated kinases is one of the greatest success stories in the “War on Cancer.” Among them, the most representative is the discovery of anaplastic lymphoma kinase (ALK) inhibitors including crizotinib and ceritinib that have benefited tens of thousands of patients with nonsmall cell lung cancer.

Received March 18, 2022
Accepted September 30, 2022

DOI https://doi.org/10.1055/s-0042-1758542.
ISSN 2628-5088.

© 2022. The Author(s).

This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Georg Thieme Verlag KG, Rüdigerstraße 14, 70469 Stuttgart, Germany
The clinical use of crizotinib (Xalkori) as a prescription medicine against ALK\textsuperscript{+} or ROS1\textsuperscript{+} metastatic NSCLC has generated a great success. However, the emergence of drug resistance appears lately, and appropriately one-third of crizotinib-resistant patients develop point mutations within the ALK kinase domain after 1 to 2 years of treatment with the drug.\textsuperscript{2} Initially, the most frequent gatekeeper mutation L1196M and mutation C1156Y were found in the kinase domain of EML4-ALK,\textsuperscript{3} followed by various other resistance mutations, such as F1174L, K1062M, G1269A, G1202R, S1206Y, L1152R, and insertion mutation 1151Tins.\textsuperscript{4}

The second generation of ALK inhibitor ceritinib (LDK-378) can effectively inhibit several crizotinib-resistant mutations (e.g., L1196M and G1269A), but fails to overcome some other resistant ALK mutants, including G1202R and F1174C.\textsuperscript{5} Inspired, lorlatinib, approved by the Food and Drug Administration (FDA) in 2018, is a third-generation macrocyclic ALK inhibitor for ALK/ROS1 cancer therapy. It is a second-line treatment for patients with advanced ALK-positive NSCLC,\textsuperscript{6} and becomes a first-line treatment for the disease in March 2021.\textsuperscript{7}

Originally, ALK was discovered in 1994 in anaplastic large-cell lymphomas (ALCLs) as a part of nucleophosmin (NPM)--ALK fusion protein.\textsuperscript{8} It is a transmembrane receptor tyrosine kinase, which belongs to the member of the insulin receptor superfamily. It consists of an extracellular ligand-binding domain, a transmembrane domain, a juxtamembrane domain, an intracellular kinase domain, and a C-terminal tail. A complete picture of ALK signaling can be pieced together through the study of multiple forms of activated ALK (fusion proteins, cancer-associated mutants, and amplifications), albeit with certain challenges.\textsuperscript{1} Interestingly, the identification of ALK fused to NPM in ALCL enabled the first roles of ALK as the fusion protein in the field of oncology.\textsuperscript{8} ALK plays an important role in many tumor types, such as NSCLC, ALCL, inflammatory myofibroblastic tumor (IMT), and more. This makes ALK an attractive target for cancer treatment.\textsuperscript{9} However, the efficacy of targeting ALK using ALK inhibitors, such as crizotinib mentioned above, is always limited by the quick emergence of drug resistance.\textsuperscript{10,11} The emergence of drug resistance has prompted the discovery of a new generation of ALK inhibitors.

**ALK Structure**

Virtually, ALK fusion proteins share many standard features (\textsuperscript{–}Fig. 2): (1) the transcription of the chimeric protein is...
driven by an ectopic/partner promoter; (2) the localization of these proteins is largely determined by the N-terminus partner region; and (3) the presence of an oligomerization domain by the ALK partner protein, which induces auto-phosphorylation and activation of the ALK kinase domain. The N-terminal region of human ALK (h-ALK) comprises two MAM domains (amino acids 264–427 and 480–626), a low-density lipoprotein class A (LDLa) domain (amino acids 453–471), and a glycine-rich (G-rich) region (amino acids 816–940). A transmembrane-spanning segment connects the extracellular region with the protein tyrosine kinase domain (amino acids 1116–1383)-containing intracellular region. The signal peptide (amino acids 1–16), the glycine-rich domain (amino acids 63–334), and the kinase domain (amino acids 510–777) are located in the intracellular C-terminal region of the protein. The 2:5 chromosomal translocation is frequently associated with ALCLs. The translocation creates a fusion gene consisting of ALK and NPM, and the 3′ portion of NPM is fused to the 5′ chromosomal translocation is from chromosome 5. This fusion gene consisting of ALK and NPM, and the 3′ portion of NPM is fused to the 5′ chromosomal translocation is from chromosome 5.

Fig. 2 Diagram of inferred interactions between human anaplastic lymphoma kinase (ALK) catalytic core residues, ATP, and a protein substrate. (A) Ribbon diagram of human ALK. The small lobe is dominated by a five-stranded antiparallel β-sheet, which is represented by number 1–5 in N-lobe. (B) Orange lines denote the residues (space-filling models) that constitute the catalytic and regulatory spines. (C) Two-dimensional diagram of the inferred interactions. Catalytically important residues that are in contact with ATP and the protein substrate occur within the light khaki background. Secondary structures and residues that are involved in regulation of catalytic activity occur within the gray background. Hydrophobic interactions between the HRD motif (the first D of K/D/D), the DFG motif (the second D of K/D/D), and the α-helix are shown by the double arrows, while polar contacts are shown by dashed lines. Pho is the phosphate attached to Tyr1283. (Adapted from Roskoski 201314 copyright Pharmacological Research.)

ALK Signaling

ALK signaling is a part of an extended family of proteins that control aspects of cell growth, differentiation, antiapoptotic signal, and development. Similar to the great majority of typical and oncogenic tyrosine kinases, ALK fusions activate many different pathways that are strictly interconnected and overlapping, including the Ras/Raf/MEK/ERK1/2 pathway, the JAK/STAT pathway, the PI3K/Akt (PKB) pathway, and the PLC-γ pathway. In addition, Akt, a protein serine/threonine kinase, binds phosphatidylinositol bisphosphate or trisphosphate with high affinity, which is also known as protein kinase B (PKB) and has some contact with ALK. The Ras–ERK pathway, JAK3–STAT3 pathway, and the PI3K–Akt pathway have many points of interaction to mediate the effects of ALK activity. The Ras–ERK pathway is essential for ALCL proliferation, whereas the JAK3–STAT3 pathway and the PI3K–Akt pathway are vital primarily for cell survival and phenotypic changes.

Downstream Regulation of ALK Signaling in Cancers

ALK and its mutants, F1174L and K1062M, were found stably expressed in NIH3T3 cells, and shows that the downstream molecules of ALK signaling, including AKT, mammalian target of rapamycin (mTOR), sonic hedgehog, JUNB, CRKL–C3G (also known as RAPGEF1)–RAP1 GTPase, and mitogen activated protein kinase (MAPK) signaling cascades, affected cell growth, transformation, and antiapoptotic signaling.

ALK Variants and Drug Resistance

Point mutations and insert mutations have become an epidemic of drug resistance problems. Crizotinib-resistant acquired secondary mutations of ALK have been identified in patients with ALK-positive NSCLC who developed disease progression. EML4–ALK, for example, is an oncoprotein found in 4 to 5% of NSCLC. This fusion gene with C1156Y mutant and L1196M mutant developed independently in subclones of the tumor and conferred marked resistance to two different ALK
inhibitors. L1196M and C1156Y are most frequent gatekeeper mutations of ALK in NSCLC patients during the relapse phase of treatment with crizotinib (Xalkori), and after that, various resistance mutations were identified, including F1174L, G1269A, G1202R, S1206Y, L1152R, R1275Q, and insertion mutation 1151Tins. Among patients treated with the second-generation anaplastic lymphoma tyrosine kinase inhibitors (ALK-TKIs), the incidence of acquired mutations increases to 50 to 70%, with G1202R being as the most common mutation. Resistance mutations to other ALK-TKIs include G1202R/I1171N (alectinib), D1203N/E1210K (brigatinib), and G1202R/F1174L/I1171N (alectinib resistance).

Mechanisms of acquired resistance of ALK-TKIs include ALK gene alterations, such as ALK point mutations, fusion gene copy number gain, and activation of bypass signaling through activation of other oncogenes (Table 1). The most important main five-point mutations (Table 2) represent that the residues Cys1156, Leu1152, Leu1196, Gly1202, Gly1269, Ser1206, Phe1174 in C1156Y, L1152Y, L1196M, G1202R, G1269A, S1206Y, and F1174L. Point mutations will be replaced by tyrosine, tyrosine, methionine, arginine, alanine, tyrosine, and leucine, respectively.

L1196M is the most frequent gatekeeper mutation of ALK, which is analogous to T790M in epidermal growth factor receptor (EGFR) and T315I in ABL. To overcome crizotinib resistance to ALK L1196M, pharmacologists have designed some new second-generation ALK inhibitors, but they were unsuccessful until ceritinib was approved in 2014. In addition, inhibitors of 7b and 001–17, designed by some researchers based on target-based drug design, showed good anti-L1196M resistance mutations (Fig. 6). Their resistance to L1196M mutation may be attributed to the improved hydrophobic interactions of the inhibitors with key residues in ALK (Leu1122, Met1199, Leu1122, Phe1271, and Lys1150), suggesting that the ensemble docking, based on multiple protein structures and target-based drug design, may be essential in the discovery of new generation of ALK-TKIs.

In recent research of crizotinib-resistant mutants of EML4-ALK, Ni et al found that F1174 is at the loop C-terminal to the α-helix C and forms a hydrophobic patch with its neighboring residues including F1271 of the DFG motif. F1174L may stabilize an active conformation that is more oncogenic and less favored for crizotinib binding. F1174L mutation has been identified as an acquired secondary resistance mechanism to crizotinib and diminished crizotinib-mediated inhibition of ALK signaling and blocked apoptosis owing to the increase of adenosine triphosphate-binding affinity. Similarly, 001–17 also induces dramatic conformational transition and stabilizes unique DFG-shifted loop conformation, enabling persistent sensitivity to different genetic mutations in ALK.

ALK-G1202K mutation may be a novel mechanism of alectinib resistance. G1202R is located in the kinase domain of the ALK protein, and contributes to resistance of the first and second generation of kinase inhibitors. ALK-G1202del confers moderate resistance to second-generation ALK-TKIs. Although many cases have suggested an important role of G1202, the effect of other unknown mutation(s) at G1202 on the available ALK-TKIs remains inconclusive. Notably, lorlatinib has good clinical outcome against the highly resistant G1202R mutation, and is sensitive to three novel compound mutations found in tumor biopsies of patient (F1174L/G1202R, L1196M/D1203N, C1156Y/G1269A, G1202R/S1206Y). However, resistance to lorlatinib has emerged in ALK-L1256F, a single mutant, which can be confirmed by some computational simulations.
Fig. 4  Signaling downstream of ALK. ALK mediates signaling via the JAK–STAT, JUN, Ras–MAPK, PI3K–mTOR, PLCγ, and RAP1 pathways. ALK, anaplastic lymphoma kinase; CDC42, cell division control protein 42; C/EBPβ, CCAAT/enhancer-binding protein-β; FOXO, forkhead box O; FRS2, fibroblast growth factor receptor substrate 2; GRB2, growth factor receptor-bound protein 2; GSK3β, glycogen synthase kinase 3β; IRS1, insulin receptor substrate 1; JNK, JUN N-terminal kinase; mTOR, mammalian target of rapamycin; NF-κB, nuclear factor-κB; NIPA, nuclear interacting partner of ALK; PLCγ, phospholipase Cγ; SHH, sonic hedgehog.

Fig. 5  Intratumoral heterogeneity and paradigm of future treatment of patients with ALK mutant NSCLC. Each colored ball represents a distinct clone with a newly acquired resistance mechanism. ALK, anaplastic lymphoma kinase; NSCLC, non-small cell lung cancer.
Faced with the endless stream of new ALK mutations, the key challenge lies in a rapid identification of which kinase domain mutations can be classified as drug resistance drivers. Thus, new technologies, such as molecular dynamics simulations, structural bioinformatics methods based on evolutionary analyses, network analysis, and machine learning, have been applied to address this issue.

With computational studies of ALK mutations, some novel point mutations have been revealed. R1192P mutation emerged at the start of the β4 strand of the kinase domain, and increases the $k_{cat}$ in the nonphosphorylated ALK tyrosine kinase domain by 15-fold. R1192P mutation occurs not only in neuroblastic tumors, but also in advanced NSCLC, and might predict sensitivity to alectinib and brigatinib.

**Insert Mutation**

ALK insert mutation 1151Tins is one of the crizotinib-resistant mutations in ALK-positive NSCLC. T1151 position in the protein is shown in Fig. 7. T1151 insertion is predicted to disrupt a critical hydrogen bond between T1151 and the...
The location of E1129 on the P-loop, adjacent to catalytic Lys1150, suggested that this insertion may lead to changes in the affinity of ALK for ATP. To date, ALK insert mutation 1151Tins has been rarely found, and only confers resistance to crizotinib and ceritinib. However, in 2021, Kobayashi et al described a rare case of uterine metastasis in a patient with ALK-rearranged NSCLC. L1151Tins was observed from the tissue of uterine metastasis, and was considered to be a crizotinib- and alectinib-resistant mutation. Besides, some new insert mutations have been discovered. L1196Q insertion is resistant to lorlatinib and can be detected after alectinib and ceritinib therapy. P1094H insertion was acquired following crizotinib and alectinib therapy and was found to induce resistance to ceritinib.

**ALK Amplification Mutation**

Genetic dissection revealed a hybrid gene (NPM-ALK) at the t(2;5)(p23;q35) chromosomal translocation breakpoint, comprising a fusion of a nucleolar protein gene NPM and a part of a gene coding ALK, a novel tyrosine kinase. In 2007, Soda et al reported a fusion gene containing part of the EML4 gene and ALK gene in NSCLC cells. These hybrid proteins undergo spontaneous dimerization, ultimately leading to a constitutive enzymatic activation of the ALK tyrosine kinase domain and autophosphorylation. Katayama et al revealed that a growing number of fusion copy of ALK gene was

| Kinase     | Location                        |
|------------|---------------------------------|
| ALK L1196M | Gatekeeper mutation             |
| ALK C1156Y | N-terminal to the α-helix       |
| ALK F1174L | C-terminal to the α-helix       |
| ALK G1269A | ATP-binding pocket              |
| ALK R1275Q | Vicinity of the DFG motif       |
| ALK T1151ins | N-terminal to the α-helix     |

Abbreviation: ALK, anaplastic lymphoma kinase.

Table 2 - The location of five-point mutations and one insertion mutation

Fig. 6 - Docking model of (A) compound 7b (light blue) and (B) 001–17 (light blue) in X-ray structure of crizotinib-bound ALK (PDB ID: 2XP2). Critical hinge hydrogen bond interactions are shown in dotted lines (gray). Pymol software was used to generate the picture. (C) Two-dimensional schematic diagram of the binding patterns of 001–17. (D) Chemical structures of 001–17 and 7b. ALK, anaplastic lymphoma kinase.
associated with mechanisms of resistance to crizotinib in a cell model of NSCLC.\textsuperscript{55} With the increasing adoption of next-generation sequencing, distinct fusion partners identified in ALK-positive NSCLC have expanded to approximately 90 (\textsuperscript{-Table 3}). EML4-ALK still accounts for approximately 85\% of the fusion variants in ALK-positive NSCLC. Chromosomal rearrangements in ALK gene have been also detected in ALCL, IMT, NSCLC, lung adenocarcinoma, and esophageal squamous cell cancer.

EML4-ALK v1 (E13, A20) and EML4-ALK v3a/b (E6, A20) variants account for 70 to 80\% of all EML4-ALK variants, and the third most common variant is EML4-ALK v2, followed by EML4-ALK v5.\textsuperscript{56} Horn et al proposed that most of EML4-ALK variants confer similar level of resistance to individual ALK-TKIs.\textsuperscript{57} Against G1202R mutation, lorlatinib and brigatinib show similar potency within the context of EML4-ALK v1.\textsuperscript{57} Lorlatinib’s potency decreased on the premise of EML4-ALK v3, and this may be caused by differences in stability of intrinsic protein among the variants. EML4-ALK v1 and v3 could form membraneless cytoplasmic granules, which act as a center for organization and activation of downstream signaling pathway components associated with resistance, like RAS.\textsuperscript{58} Consequently, ALK-TKI’s resistance is multifactorial and the background of fusion variant should be taken into consideration when interpreting ALK resistance mutations.

TP53 (tumor protein p53) is a tumor suppressor gene. TP53 mutations reduced the sensitivity of ALK-TKIs,\textsuperscript{59} and\textsuperscript{60} patients harboring with both TP53 mutations and EML4-ALK v3 were associated with a worse poor prognosis.\textsuperscript{60} Preclinical data indicated that the combination of ALK-TKIs with proteasome inhibitor may be useful in generating TP53-independent apoptosis.

**ALK Signaling through Activation of Other Oncogenes**

ALK-TKIs are emerging as effective clinical therapies for cancers containing genetic rearrangements in ALK, including NSCLC, IMT, and ALCL. However, the clinical success of this therapeutic approach is uniformly limited by the development of drug resistance. All the different ALK fusion proteins regulate through a multitude of downstream pathways, including activation of MET, EGFR, SRC, and IGF-1R.\textsuperscript{108} EGFR activation is the most common downstream pathway, accounting for approximately 30\% of patients with crizotinib resistance. It is mainly achieved by up-regulating the expression of EGFR and its ligands. HER2/3 belongs to the family of HER and EGFR. Some studies have found that HER3 ligand neuroregulatory protein 1 (neuroregulin1, NRG1) is overexpressed in drug-resistant crizotinib cells, which can promote the interaction between HER2 and HER3 and affect the downstream pathway, leading to the drug resistance.\textsuperscript{21}

MET activation has been regarded as a bypass pathway in EGFR-mutant NSCLC and has been detected in 5 to 20\% of resistance cases.\textsuperscript{109} Compared with EGFR-mutant NSCLC, relatively fewer papers have made contribution of aberrant MET activation to resistance in ALK-positive NSCLC. Recently, Molina-Vila and colleagues found MET alterations in 4 out of 12 (33\%) fusion-positive patients after progression on TKIs.\textsuperscript{110} In addition, Hata and coworkers analyzed more than 200 resistance tissue and plasma specimens and discovered that approximately 15\% of tumor biopsies from patients were identified MET amplification and a novel ST7-MET rearrangement has been detected in two cases. Thus, MET amplification can mediate resistance to ALK-TKIs to some extent and suggests that the ALK/ROS1/MET TKI crizotinib may be able to overcome MET-driven resistance.\textsuperscript{111,112}

Karaca Atabay et al identified that the loss of PTPN1 and PTPN2, two kinds of protein tyrosine phosphatases, culminate in crizotinib resistance. Downstream signaling analysis showed that the deletion of PTPN1 or PTPN2 would hyper-activate SHP2, the MAPK, and JAK/STAT pathways, and lead to crizotinib resistance. Hence, a combined blockade of SHP2 potentiates the efficacy of ALK inhibitor in antiresistance.\textsuperscript{113}

NF2 is a known tumor-suppressing gene that acts as a guardian in the Hippo signaling pathway and approximately 2\% of breast cancer patients harbor NF2 mutation.\textsuperscript{114} Fri-boulet and his coworkers knock out NF2 gene in the H3122
cell line and identified that NF2 loss of function, as a novel bypass mechanism of resistance to lorlatinib, was sensitized by mTOR inhibition both in vitro and in vivo, which offers a novel potential treatment approach for lorlatinib resistance.\(^ {115} \)

### Current Solutions to Overcome Drug Resistance

The problem of resistance to ALK inhibitors has become an important obstacle limiting the development of ALK inhibitors. First and foremost, the urgent and essential thing is to develop approaches for rapidly identifying which kinase domain mutations can be classified as cancer drivers and the resistance mechanisms. Due to the continuous research into the mechanism of ALK-TKI resistance, many solutions have been found. The acquired resistance mechanisms of ALK-TKIs have been fully illustrated, and some new strategies to overcome drug resistance are reviewed below. The potent ALK-TKIs that overcome drug resistance are also listed in – Fig. 8.

### Develop Smaller and More Compact Macro cyclic ALK-TKIs

The current ALK inhibitors on the market share some common characteristics, including large and loose molecular structures, and some motifs near or across the hydrophobic posterior capsule. These characters make them more susceptible to drug-resistant mutations. Thus, new inhibitors with increasingly compact structures have been designed. In 2020, TPX-0131, a macrocyclic molecule, was reported as a next-generation ALK inhibitor (– Fig. 8). TPX-0131 is designed to fit within the ATP-binding boundary to inhibit ALK fusion proteins and is more potent than all FDA-approved ALK-TKIs against WT ALK and many types of ALK resistance mutations.\(^ {116,117} \)

### Table 3 Recurrent chromosomal translocations and fusion proteins involving ALK gene in human cancers

| Fusion protein | Disease | Refs. |
|---------------|--------|------|
| NPM-ALK       | ALCL   | 8    |
| ALO17-ALK; two variants | ALCL | 60   |
| TFG-ALK; three variants | ALCL | 61.62 |
| MSN-ALK       | ALCL   | 63.64 |
| TPM3-ALK      | ALCL   | 65.66 |
| TPM4-ALK      | ALCL   | 67    |
| ATG3ALK       | ALCL   | 68–70 |
| MYC9-ALK      | ALCL   | 71    |
| CLTC1-ALK     | ALCL   | 72    |
| EML4-ALK; 13 variants | NSCLC | 54,73 |
| TFG-ALK       | NSCLC  | 73    |
| TFG-ALK       | NSMM   | 74    |
| KIF5B-ALK     | NSCLC  | 75,76 |
| KLC1-ALK      | NSCLC  | 77    |
| PTPN3-ALK     | NSCLC  | 78    |
| TPM3-ALK      | IMT    | 79    |
| TPM4-ALK      | IMT    | 79    |
| CTC1-ALK      | IMT    | 80,81 |
| ATIC-ALK      | IMT    | 82    |
| CARS-ALK      | IMT    | 60,83 |
| RANBP2-ALK    | IMT    | 84    |
| SEC31L1-ALK   | IMT    | 85    |
| NPM-ALK       | DLBCL  | 86,87 |
| CLTC1-ALK     | DLBCL  | 88    |
| SQSTM1-ALK    | DLBCL  | 89    |
| SEC31A-ALK    | DLBCL  | 90    |
| EML4-ALK      | BRCA   | 91    |
| EML4-ALK      | CRC    | 91    |
| C2orf44-ALK   | CRC    | 92    |
| TPM4-ALK      | ESCLC  | 93,94 |
| VCL-ALK       | RCC    | 95    |
| HIP1-ALK      | NSCLC  | 96    |
| SEC31A-ALK    | NSCLC  | 97    |
| CLX1-ALK      | NSCLC  | 98    |
| VKORC1L1-ALK  | NSCLC  | 99    |
| DYSF-ALK      | NSCLC  | 100   |
| ITGAV-ALK     | NSCLC  | 100   |
| TNI2P2-ALK    | NSCLC/ LUAD | 101 |
| ERC1-ALK      | NSCLC/ LUAD | 102 |
| FBN1-ALK      | NSCLC/ LUAD | 102 |
| TRIM66-ALK    | NSCLC/ LUAD | 102 |
| SWAP70        | NSCLC/ LUAD | 102 |
| WNK3          | NSCLC/ LUAD | 102 |

(Continued)

### Table 3 (Continued)

| Fusion protein | Disease | Refs. |
|---------------|--------|------|
| CHRNA7-ALK    | NSCLC  | 103   |
| LIMD1-ALK     | NSCLC  | 103   |
| TTC271-ALK    | NSCLC  | 103   |
| LINC00327-ALK | NSCLC  | 103   |
| SORCS1-ALK    | NSCLC  | 103   |
| LINC00211-ALK | NSCLC  | 103   |
| KIF5B-ALK     | ALKPH  | 105   |
| LRRFIP1-ALK   | IMT    | 106   |
| PPP1CB-ALK    | CGM    | 107   |

Abbreviations: ALCL, anaplastic large cell lymphoma; ALKPH, ALK-positive histiocytosis; BRCA, breast cancer; CGM, congenital glioblastoma; CRC, colorectal cancer; CSF, cerebrospinal fluid; DLBCL, diffuse large B cell lymphoma; ESCL, esophageal squamous cell cancer; IMT, inflammatory myofibroblastic tumor; LUAD, lung adenocarcinoma; NSCLC, non-small cell lung cancer; NSMM, non-secretary multiple myeloma; RCC, renal cell cancer.
Selective Degradation of Mutant Kinase Variants by PROTACs

Proteolysis targeting chimeras (PROTACs), a technology of modulating a protein of interest through degradation, has become one of the most promising cancer therapeutic strategies. PROTACs consist of three parts, a ligand for binding targets, an E3-ubiquitin ligase ligand for hijacking an endogenous E3 ligase, and an optimal linker that connects these two moieties, resulting in the ubiquitination and degradation of the targeted protein via the ubiquitin–proteasome system.

PROTACs have been used successfully to selectively degrade ALK protein since 2018. In Jin’s laboratory, two ALK degraders, MS4077 and MS4078 (Fig. 8), have been designed to decrease the active oncogenic ALK fusion proteins in SU-DHL-1 lymphoma and NCI-H2228 lung cancer cells, and to mediate ubiquitination and degradation of NPM-ALK and EML4-ALK in vitro. However, MS4077 and MS4078 do not significantly improve the antiproliferative effects against ALK mutant lung cancer cells in comparison to ceritinib.

The Jiang group synthesized a series of ALK PROTACs by combining brigatinib and VHL-1 and discovered SIAIS117 as a potential treatment for drug resistance of ALK-TKIs (Fig. 8). This compound shows strong in vitro anti-G1202R resistance mutations. In 2021, the Jiang’s group also reported SIAIS001, an alectinib-based ALK PROTAC, which can promote G1/S phase arrest and shows much better growth inhibition effects than alectinib (Fig. 8). In light of the rapid development of the PROTACs technology, more and more ALK degraders are being designed and synthesized to anticipate in clinical trials and will be used in clinical practice shortly.

Conclusions and Perspectives

There is no doubt that ALK, a potent carcinogenic driver gene, plays an important role in various types of human cancers. Unfortunately, rapid emergence of the drug resistance could significantly affect the survival of patients treated with ALK-TKIs. Based on the structures of ALK and their variants, as well as the net of ALK-mediating signal transduction, mechanisms of drug resistance, such as point mutations, amplification mutations, activation of bypass signaling, and NF2 loss-of-function mutations, etc., have been discovered.

Based on the crystal structure of the ALK, smaller and more compact macrocyclic ALK-TKIs, including Repotrectinib and TPX-0131, have been designed to positively overcome drug resistance. The PROTAC strategy offers another promising means to overcome the issue of drug resistance. It can be used to degrade ALK driver proteins, and thus evade drug resistance. Although PROTAC-designed ALK inhibitors only have good potency in vitro, ALK PROTACs has been considered to have great potential in clinical therapy. Furthermore, computational modeling and machine learning can also be utilized for the discovery and development of novel ALK drugs. To sum up, there is still a long way to go before we can successfully tackle cancer, and there is much more research needed to understand and overcome resistance to ALK-TKIs.
Conflict of Interest
The authors declare no conflict of interest.

References
1 Lovly CM, Pao W. Escaping ALK inhibition: mechanisms of and strategies to overcome resistance. Sci Transl Med 2012;4(120):120ps2
2 Shaw AT, Engelman JA. ALK in lung cancer: past, present, and future. J Clin Oncol 2013;31(08):1105–1111
3 Choi YL, Soda M, Yamashita Y, et al. ALK Lung Cancer Study Group. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med 2010;363(18):1734–1739
4 Hallberg B, Palmer RH. Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology. Nat Rev Cancer 2013;13(10):685–700
5 Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov 2014;4(06):662–673
6 Li J, Pithaval YK, Gong J, LaBadie RR, Mfopoulos JK, Chen J. The effect of modestin on the safety and pharmacokinetics of lorlatinib: a phase I study in healthy participants. Clin Pharmacokinet 2021;60(10):1303–1312
7 Shaw AT, Bauer TM, de Marinis F, et al. CROWN Trial Investigators. First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer. N Engl J Med 2020;383(21):2018–2029
8 Morris SW, Kirstein MN, Valentine MB, et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin’s lymphoma. Science 1994;263(5151):1281–1284
9 Morris SW, Kirstein MN, Valentine MB, et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin’s lymphoma. Science 1994;263(5151):1281–1284
10 Rodig SJ, Shapiro GL. Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases. Curr Opin Investig Drugs 2010;11(12):1477–1490
11 Doebele RC, Pilling AB, Aisner DL, et al. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin Cancer Res 2012;18(05):1472–1482
12 Lovly CM, McDonald NT, Chen H, et al. Rationale for co-targeting IGFR-1 and ALK in ALK fusion-positive lung cancer. Nat Med 2009;20(09):1027–1034
13 Zhang C, Han XR, Yang X, et al. Proteolysis Targeting Chimeras (PROTACs) of anaplastic lymphoma kinase (ALK). Eur J Med Chem 2018;151:304–314
14 Roskoski R Jr. Anaplastic lymphoma kinase (ALK): structure, oncogenic activation, and pharmacological inhibition. Pharmacol Res 2013;68(01):68–94
15 Lai AC, Crews CM. Induced protein degradation: an emerging drug discovery paradigm. Nat Rev Drug Discov 2017;16(02):101–114
16 Wellstein A, Toretsky JA. Hunting ALK to feed targeted cancer therapy. Nat Med 2011;17(03):290–291
17 Isozaki H, Takigawa N, Kiura K. Mechanisms of acquired resistance to ALK inhibitors and the rationale for treating ALK-positive lung cancer. Cancers (Basel) 2015;7(02):763–783
18 Liu J, Ma S. Recent development in the discovery of anaplastic lymphoma kinase (ALK) inhibitors for non-small cell lung cancer. Curr Med Chem 2017;24(06):590–613
19 Chen Y, Takita J, Choi YL, et al. Oncogenic mutations of ALK kinase in neuroblastoma. Nature 2008;455(7215):971–974
20 Sasaki T, Okuda K, Zheng W, et al. The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers. Cancer Res 2010;70(24):10038–10043
21 Katayama R, Shaw AT, Khan TM, et al. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers. Sci Transl Med 2012;4(120):120ra17
22 Mehman C, Chaahane N, Lacave R, et al. Ceritinib ALK T1151R resistance mutation in lung cancer with initial response to brigitinib. J Thorac Oncol 2019;14(05):e95–e96
23 Pan Y, Deng C, Qiu Z, Cao C, Wu F. The resistance mechanisms and treatment strategies for ALK-rearranged non-small cell lung cancer. Front Oncol 2021;11:713530
24 Sasaki T, Koivunen J, Ogino A, et al. A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. Cancer Res 2011;71(18):6051–6060
25 Basit S, Ashraf Z, Lee K, Latif M. First macrocyclic 3rd-generation ALK inhibitor for treatment of ALK/ROS1 cancer: clinical and designing strategy update of lorlatinib. Eur J Med Chem 2017;134:348–356
26 Chand D, Yamazaki Y, Ruuth K, et al. Cell culture and Drosophila model systems define three classes of anaplastic lymphoma kinase mutations in neuroblastoma. Dis Model Mech 2013;6(02):373–382
27 Mossé YP, Lautenslager M, Longo L, et al. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 2008;455(7215):930–935
28 Schönerr C, Ruuth K, Yamazaki Y, et al. Activating ALK mutations found in neuroblastoma are inhibited by Crizotinib and NVP-TAE684. Biochem J 2011;440(03):405–413
29 George RE, Sanda T, Hanna M, et al. Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature 2008;455(7215):975–978
30 Martinsson T, Eriksson T, Abrahamsson J, et al. Appearance of the novel activating F1174S ALK mutation in neuroblastoma correlates with aggressive tumor progression and unresponsiveness to therapy. Cancer Res 2011;71(01):98–105
31 Carén H, Abel F, Kogner P, Martinsson T. High incidence of DNA mutations and gene amplifications of the ALK gene in advanced sporadic neuroblastoma tumours. Biochem J 2008;416(02):153–159
32 Janoueix-Lerosey I, Lecuin D, Brugier L, et al. Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature 2008;455(7215):967–970
33 Schulte JH, Bachmann HS, Brockmeyer B, et al. High ALK receptor tyrosine kinase expression supersedes ALK mutation as a determining factor of an unfavorable phenotype in primary neuroblastoma. Clin Cancer Res 2011;17(15):5082–5092
34 Heuckmann JM, Hölzel M, Sos M, et al. Mutations conferring differential resistance to structurally diverse ALK inhibitors. Clin Cancer Res 2011;17(23):7394–7401
35 Murugan AK, Xing M. Anaplastic thyroid cancers harbor novel oncogenic mutations of the ALK gene. Cancer Res 2011;71(13):4403–4411
36 McDuff FK, Lim SV, Dalbay M, Turner SD. Assessment of the transforming potential of novel anaplastic lymphoma kinase point mutants. Mol Carcinog 2013;52(01):79–83
37 Choi HG, Ren P, Adrian F, et al. A type-II kinase inhibitor capable of inhibiting the T315I “gatekeeper” mutant of Bcr-Abl. J Med Chem 2010;53(15):5439–5448
38 Guan H, Du Y, Ning Y, Cao X. A brief perspective of drug resistance toward EGFR inhibitors: the crystal structures of EGFRs and their variants. Future Med Chem 2017;9(07):693–704
39 Marsilje TH, Pei W, Chen B, et al. Synthesis, structure–activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-[2-(isopropoxy)-5-methyl-4-([piperidin-4-yl]phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) currently in phase 1 and phase 2 clinical trials. J Med Chem 2013;56(14):5675–5690
40 Wang Y, Zhang G, Hu G, et al. Design, synthesis and biological evaluation of novel 4-arylaminopyrimidine derivatives possessing a hydrazono moiety as dual inhibitors of L1196M ALK and ROS1. Eur J Med Chem 2016;123:80–89
Hallmarks of ALK Inhibitors with Its Quick Emergence of Drug Resistance

Qiu et al.

Horn L, Whisenant JG, Wakelee H, et al. Monitoring therapeutic

Zhang SS, Nagasaka M, Zhu VW, Ou SI. Going beneath the tip of

Katayama R, Khan TM, Benes C, et al. Therapeutic strategies to

Soda M, Choi YL, Enomoto M, et al. Identification of novel fusion

Heregger R, Huemer F, Hutarew G, et al. Sustained response to

Baglivo S, Ricciuti B, Ludovini V, et al. Dramatic response to

Ni Z, Wang X, Zhang T, Jin RZ. Molecular dynamics simulations

Furuta H, Araki M, Masago K, et al. Novel resistance mechanisms

Okada K, Araki M, Sakashita T, et al. Prediction of ALK mutations

Tabbó F, Reale ML, Bironzo P, Scagliotto GV. Resistance to

Zhu VW, Nagasaka M, Madison R, Schrock AB, Cui J, Ou SI. A novel

Bresler SC, Wood AC, Haglund EA, et al. Differential inhibitor

Yang PCR, Bao H, Wu X, et al. Identification of novel alecinib-

A 2011;108(18):7535-7541

Koizumi T. Response to lorlatinib on a patient with ALK-

Tulpule A, Guan J, Neel DS, et al. Kinase-mediated RAS signaling

Tanimoto A, Matsumoto S, Takeuchi S, et al. Proteasome inhibi-

Cools J, Wlodarska I, Somers R, et al. Identification of novel fusion

Masood A, Christ T, Asif S, et al. Non-secretory multiple myeloma

Tort F, Pinyol M, Pulford K, et al. Molecular characterization of a

Siebert R, Gesk S, Harder L, et al. Complex variant translocation t

Tort F, Campo E, Pohlian B, Hsi E. Heterogeneity of genomic

Lamant L, Dastugue N, Pulford K, Delso G, Mariamé M. A new

Colleoni GW, Bridge JA, Garicochea B, Liu J, Filippa DA, Ladanyi M.

Ma Z, Cools J, Wlodarska I, Somers R, et al. Identification of a new

Cools J, Wlodarska I, Takeuchi K, et al. Identification of a new

Touriol C, Greenland C, Lamant L, et al. Further demonstration of

Lamant L, Gascoyne RD, Duplantier MM, et al. Non-muscle

Barbran-Laponnaz S, Guerini A, Constant A, et al. A new ALK

Tort F, Campo E, Pohlian B, Hsi E. Heterogeneity of genomic

Zhang SS, Nagasaka M, Zhu VW, Ou SI. Going beneath the tip of

Pharmaceutical Fronts Vol. 4 No. 4/2022 © 2022. The Author(s).
diagnostic system for ALK-positive lung cancer. Clin Cancer Res 2009;15(09):3143–3149
76 Wong DW, Leung EL, Wong SK, et al. A novel KIF5B-ALK variant in nonsmall cell lung cancer. Cancer 2011;117(12):2709–2718
77 Togashi Y, Soda M, Sakata S, et al. KLK1-ALK: a novel fusion in lung cancer identified using a formalin-fixed paraffin-embedded tissue only. PLoS One 2012;7(02):e31323
78 Jung Y, Kim P, Jung Y, et al. Discovery of ALK-PTPN3 gene fusion from human non-small cell lung carcinoma cell line using next generation RNA sequencing. Genes Chromosomes Cancer 2012;51(06):590–597
79 Lawrence B, Perez-Atayde A, Hibbard MK, et al. TPM3-ALK and TPM4-ALK oncogenes in inflammatory myofibroblastic tumors. Am J Pathol 2000;157(02):377–384
80 Bridge JA, Kanamori M, Ma Z, et al. Fusion of the ALK gene to the clathrin heavy chain gene, CLTC, in inflammatory myofibroblastic tumor. Am J Pathol 2001;159(02):411–415
81 Patel AS, Murphy KM, Hawkins AL, et al. RANBP2 and CLTC are involved in ALK rearrangements in inflammatory myofibroblastic tumors. Cancer Genet Cytogenet 2007;176(02):107–114
82 Debiec-Rychter M, Marynen P, Hagemeier A, Pauwels P. ALK-ATIC fusion in urinary bladder inflammatory myofibroblastic tumor. Genes Chromosomes Cancer 2003;38(02):187–190
83 Debelenko LV, Arthur DC, Pack SD, Helman LJ, Schrpm S, Tsokos M. Identification of CAR-ALK fusion in primary and metastatic lesions of an inflammatory myofibroblastic tumor. Lab Invest 2003;83(08):1255–1265
84 Marifio-Enriquez A, Wang WL, Roy A, et al. Epithelioid inflammatory myofibroblastic sarcoma: An aggressive intra-abdominal variant of inflammatory myofibroblastic tumor with nuclear membrane or perinuclear ALK. Am J Surg Pathol 2011;35(01):135–144
85 Panagopoulos I, Nilsson T, Domanski HA, et al. Fusion of the SEC31L1 and ALK genes in an inflammatory myofibroblastic tumor. Int J Cancer 2006;118(05):1181–1186
86 Onciu M, Behm FG, Downing JR, et al. ALK-positive plasmablastic B-cell lymphoma with expression of the NPM-ALK fusion transcript: report of 2 cases. Blood 2003;102(07):2642–2644
87 Adam P, Katzenberger T, Seeberger H, et al. A case of a diffuse large B-cell lymphoma of plasmablastic type associated with the t(2;5)(p23;q35) chromosome translocation. Am J Surg Pathol 2003;27(11):1473–1476
88 De Paep-Paenen M, van Krieken H, et al. ALK activation by the clathrin heavy chain gene, CLTC, in inflammatory myofibroblastic sarcoma: report of 2 cases. Blood 2003;102(07):2638–2641
89 Takeuchi K, Soda M, Togashi Y, et al. Identification of a novel fusion, SQSTM1-ALK, in ALK-positive large B-cell lymphoma. Haematologica 2011;96(03):464–467
90 Van Roosbroeck K, Cools J, Dierickx D, et al. ALK-positive B-cell lymphomas with cryptic SEC31A-ALK and NPM1-ALK fusions. Haematologica 2010;95(03):509–513
91 Lin E, Li L, Guan Y, et al. Exon array profiling detects EML4-ALK fusion in breast, colorectal, and non-small cell lung cancers. Mol Cancer Res 2009;7(09):1466–1476
92 Lipson D, Capelletti M, Yelensky R, et al. Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat Med 2012;18(03):382–384
93 Jaziri FR, Najafi Z, Malekzadeh R, et al. Identification of squamous cell carcinoma associated proteins by proteomics and loss of beta tropomyosin expression in esophageal cancer. World J Gastroenterol 2006;12(44):7104–7112
94 Du XL, Hu H, Lin DC, et al. Proteomic profiling of proteins dysregulated in Chinese esophageal squamous cell carcinoma. J Mol Med (Berl) 2007;85(08):863–875
95 Debelenko LV, Raimondi SC, Daw N, et al. Renal cell carcinoma with novel VCL-ALK fusion: new representative of ALK-associated tumor spectrum. Mod Pathol 2011;24(03):430–442
96 Fang DD, Zhang B, Gu Q, et al. HIPIP-ALK, a novel ALK fusion variant that responds to crizotinib. J Thorac Oncol 2014;9(03):285–294
97 Kim RN, Choi YI, Lee MS, et al. SEC31A-ALK fusion gene in lung adenocarcinoma. Cancer Res Treat 2016;48(01):398–402
98 Zhang M, Wang Q, Ding Y, et al. CUX1-ALK, a novel ALK rearrangement that responds to crizotinib in non-small cell lung cancer. J Thorac Oncol 2018;13(11):1792–1797
99 Zhu VW, Schroek AB, Bosemani T, Benn BS, Ali SM, Ou SI. Dramatic response to alectinib in a lung cancer patient with a novel VIKORC11-ALK fusion and an acquired ALK T1151K mutation. Lung Cancer (Auckl) 2018;9:111–116
100 Yin J, Zhang Y, Zhang Y, Peng F, Lu Y. Reporting on two novel fusions, DYSF-ALK and ITGAV-ALK, coexisting in one patient with adenocarcinoma of lung, sensitive to crizotinib. J Thorac Oncol 2018;13(03):e43–e45
101 Feng T, Chen Z, Gu J, Wang Y, Zhang J, Min L. The clinical responses of TPNI2-ALK fusion variants to crizotinib in ALK-rearranged lung adenocarcinoma. Lung Cancer 2019;137:19–22
102 Zhou X, Shou J, Sheng J, et al. Molecular and clinical analysis of Chinese patients with anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer. Cancer Sci 2019;110(10):3382–3390
103 Tian P, Liu Y, Zeng H, et al. Unique molecular features and clinical outcomes in young patients with non-small cell lung cancer harboring ALK fusion genes. J Cancer Res Clin Oncol 2020;146(04):935–944
104 Li Z, Li P, Yan B, et al. Sequential ALK inhibitor treatment benefits patient with leptomeningeal metastasis harboring non-EML4-ALK rearrangements detected from cerebrospinal fluid: a case report. Thorac Cancer 2020;11(01):176–180
105 Qiu L, Weitzman SP, Nastoupoli LJ, Williams MD, Medeiros LJ, Vega F. Disseminated ALK-positive histiocytosis with KIF5B-ALK fusion in an adult. Leuk Lymphoma 2021;62(05):1234–1238
106 Liu W, Duan Q, Gong L, et al. A novel LRFRF1-ALK fusion in inflammatory myofibroblastic tumor of hip and response to crizotinib. Invest New Drugs 2021;39(01):278–282
107 Zhong Y, Lin F, Xu F, et al. Genomic characterization of a PPP1CB-ALK fusion with fusion gene amplification in a congenital glioblastoma. Cancer Genet 2021;252:971–978
108 Crystal AS, Shaw AT, Sequist LV, et al. Patient-derived models of acquired resistance can identify effective drug combinations for cancer. Science 2014;346(6216):1480–1486
109 Wu YL, Soo RA, Locatelli G, Stammberger U, Scagliotti G, Park K. Does c-MET remain a rational target for therapy in patients with EGFR TKI-resistant non-small cell lung cancer? Cancer Treat Rev 2017;61:70–81
110 Jordana-Ariza N, Reischmann N, Esparrè C, et al. Abstract 1106: detection of MET alterations at the DNA, RNA and protein levels in NSCLC patients progressing on ALK and ROS1 targeted therapies. Cancer Res 2022;82(12, Supplement):1106
111 Sakakibara-Konishi J, Kitai H, Ikezawa Y, et al. Response to crizotinib re-administration after progression on lorlatinib in a patient with ALK-rearranged non-small cell lung cancer. Clin Lung Cancer 2019;20(05):e555–e559
112 Dagogo-Jack I, Yoda S, Lennerz JK, et al. MET alterations are a recurring and actionable resistance mechanism in ALK-positive lung cancer. Cancer Res 2022;82(12, Supplement):1106
113 Karaca Atabay E, Mecca C, Wang Q, et al. Tyrosine phosphatases regulate resistance to ALK inhibitors in ALK-anaplastic large cell lymphoma. Blood 2022;139(05):717–731
114 Lang GT, Jiang YZ, Shi JX, et al. Characterization of the genomic landscape and actionable mutations in Chinese breast cancers by clinical sequencing. Nat Commun 2020;11(01):5679
115 Recondo G, Mezquita L, Facchinetti F, et al. Diverse resistance mechanisms to the third-generation ALK inhibitor lorlatinib in ALK-rearranged lung cancer. Clin Cancer Res 2020;26(01):242–255
Cui JJ, Rogers E, Zhai D, et al. Abstract 5226: TPX-0131: a next generation macrocyclic ALK inhibitor that overcomes ALK resistant mutations refractory to current approved ALK inhibitors. Cancer Res 2020;80(16, Supplement):5226

Murray BW, Zhai D, Deng W, et al. TPX-0131, a Potent CNS-penetrant, next-generation inhibitor of wild-type ALK and ALK-resistant mutations. Mol Cancer Ther 2021;20(09):1499–1507

Sun X, Gao H, Yang Y, et al. PROTACs: great opportunities for academia and industry. Signal Transduct Target Ther 2019;4:64

Sun N, Ren C, Kong Y, et al. Development of a Brigatinib degrader (SIAIS117) as a potential treatment for ALK positive cancer resistance. Eur J Med Chem 2020;193:112190

Ren C, Sun N, Kong Y, et al. Structure-based discovery of SIAIS001 as an oral bioavailability ALK degrader constructed from Alectinib. Eur J Med Chem 2021;217:113335